

(12) UK Patent Application (19) GB (11) 2 177 096A

(43) Date of printing by UK Office 14 Jan 1987

(21) Application No 8608827

(22) Date of filing 3 Sep 1985

(30) Priority data

(31) 8422238 (32) 2 Sep 1984 (33) GB

(86) International application data
PCT/GB85/00392 En 3 Sep 1985

(87) International publication data
WO86/01533 En 13 Mar 1986

(71) Applicant
Celltech Limited

(Incorporated in United Kingdom),

244-250 Bath Road, Slough, Berkshire SL1 4DY

(72) Inventors
Michael Samuel Neuberger,
Terence Howard Rabbitts

(51) INT CL⁴ (as given by ISA)

C12N 15/00 A61K 39/395 C07K 3/18 15/00 C12N 5/00
C12P 21/00 G01N 33/563

(52) Domestic classification (Edition I)

C3H 431 642 656 675 690 B7M
C6Y 404 501 503
U1S 2419 C3H

(56) Documents cited by ISA

EP A 0150126 EP A 0090898
EP A 0125023 EP A 0068763
EP A 0120694 WO A 83/03971
EP A 0105521 WO A 84/00382


Chemical Abstracts, volume 95, no. 4, 27 July 1981,
page 363, abstract 30711m
Nature, 314 no. 6010, April 1985, pages 452-454
Nature, 314, no. 6008, 21 March 1985, pages 268-270
Nature 312, no. 5995, December 1984, pages 643-646
Nature 312, no. 5995, December 1984, pages 604-608

(58) Field of search by ISA
IPC⁴ C12N; C12P

(74) Agent and/or Address for Service
Carpmaels & Ransford, 43 Bloomsbury Square, London
WC1A 2RA.

(54) Production of chimeric antibodies

(57) A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first path which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein: b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transforming an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell line to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.



GB 2 177 096 A